Interventional Epidemiologic Research Studies of HIV/AIDS Among Pregnant Women, Children, and Adolescents; Availability of Funds

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 99102]

Interventional Epidemiologic Research Studies of HIV/AIDS Among

Pregnant Women, Children, and Adolescents; Availability of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the

availability of fiscal year (FY) 1999 funds for a cooperative agreement

program for new and competitive continuation cooperative agreements for

interventional epidemiologic research studies of HIV/AIDS among

pregnant women, children, and adolescents. This program addresses the

``Healthy People 2000'' priority areas of HIV Infection and Maternal

and Infant Health. The purpose of the program is to support researchers

in the conduct of HIV interventional epidemiologic research studies

that foster prevention of HIV infection or HIV-related disease in

infants, children, and adolescents. These include studies that address:

(I) Mother infant rapid intervention at delivery (MIRIAD), (II) follow-

up of perinatally HIV-infected children, and (III) parent communication

training interventions with longitudinal follow-up among populations of

color at high risk for infection for sexually transmitted diseases

(STD) including HIV.

Research Studies

(I) Mother Infant Rapid Intervention at Delivery (MIRIAD)

Most HIV-infected pregnant women in the United States use hospitals

for delivery, providing a crucial opportunity for systematic screening

and intervention when indicated. In

[[Page 27995]]

some parts of the country, more infants might be spared HIV infection

if the benefits of intrapartum/neonatal zidovudine (ZDV) were extended

to pregnant women with little or no prenatal care than if transmission

rates were further reduced among cohorts already receiving standard

ACTG-076 therapy.

The MIRIAD Project should assess (1) a 24-hour counseling and

voluntary rapid HIV testing program among women in labor presenting

with unknown HIV status; (2) the feasibility of obtaining informed

consent during labor (or, if not feasible, soon after birth); (3)

reasons for lack of prenatal care among these women; (4) the rapid

implementation and assessment of antiretroviral therapy--mono therapy

or more intensive regimens--given at labor and delivery or to the

neonate; (5) adherence to neonatal therapy; and (6) subsequent receipt

of antiretroviral treatment and other services for women identified as

HIV infected.

Innovative implementation strategies for the prevention of

perinatal HIV transmission in settings where many HIV-infected women

continue to receive little or no prenatal care are encouraged. Novel

approaches for rapid bedside testing of women in labor and post-test

counseling and referral/connection to care for HIV positive women and

their infants should be carefully piloted at each site during the first

12-18 months of the funding period. A sustainable full-time in-labor

(or, if not feasible, postpartum) counseling, testing and ZDV

chemoprophylaxis intervention program should be instituted according to

the standard of care at each participating site no later than 18 months

into the funding period. Late-registrant mothers presenting after 36

weeks of pregnancy with unknown HIV status should also be offered rapid

HIV testing and antiretroviral therapy during late pregnancy,

intrapartum and to the neonate.

Administration of intravenous ZDV intrapartum (if possible) and

oral ZDV to the neonate as soon as possible and within 48 hours of

birth should be recommended as the minimum standard of perinatal HIV

preventive care for HIV-infected women presenting in labor. More

intensive antiretroviral therapy such as combination therapy should be

presented as an option with possible post exposure prophylaxis benefit

over mono therapy. Perinatal HIV transmission risk associated with

various components of the antiretroviral intervention (e.g., neonatal

only administration versus intrapartum + neonatal) will be compared

while attempting to control for possible confounders. Results from

these studies should facilitate recommendations and provide

effectiveness and operational research data on rapid HIV testing and

administration of antiretrovirals among late-registrant women

presenting in delivery rooms with unknown HIV status.

At each Project site, it is expected that a minimum of 1000 women

will receive rapid HIV testing and counseling per year; and that a

minimum of 20 HIV positive mother-infant pairs will be identified

(after 36 weeks of pregnancy, during labor or within 48 hours after

birth) and enrolled in MIRIAD annually. In order to reach these numbers

and serve a large, population-based sample of disadvantaged women with

high HIV sero prevalence and inadequate prenatal care, primary project

sites are encouraged to collaborate with 2-3 other hospitals or

maternity clinics within their geographic area. In the second and third

year of the project, based on experience gained from the MIRIAD

project, funded sites will be asked to develop outreach programs to

assist other hospitals in their area implement rapid counseling and HIV

testing at labor, and delivery of peripartum antiretroviral

interventions.

Rapid testing for HIV during the peripartum period has the

potential to improve clinical outcomes for both women and their infants

but the question of how best to provide rapid HIV testing, how to

perform urgent confirmatory testing in this setting, and how to best

present women with risk/benefit information and treatment options needs

systematic research. Integration of behavioral (i.e., to assess factors

related to lack of prenatal care, counseling and testing in the

delivery setting, informed consent issues, adherence to antiretroviral

therapy in the neonatal period, enhancement of social support

mechanisms) and biomedical sciences and a multi disciplinary research

team is strongly encouraged.

II. Follow-up of Perinatally HIV-Infected Children

Competing continuation applications are invited for the continued

prospective follow-up of HIV-infected children enrolled in the

Perinatal AIDS Collaborative Transmission Study (PACTS) between 1986

and 1998. Continued research areas of interest should include

identifying maternal and early infant markers of rapid versus chronic

pediatric disease progression, investigating host-related genetic

factors related to disease progression, and assessing adherence and

responses to the newest therapeutic interventions. As this unique and

well-characterized cohort of HIV-infected children ages into

adolescence, opportunities will arise for in-depth analysis of the

interrelationships among psycho social factors, pubertal development,

and disease progression, as well as for research into behavioral

interventions to prevent sexual HIV transmission.

This continuation project will support ongoing data collection and

analysis for the HIV-infected children and up to two comparison groups:

an HIV exposed but uninfected group (1:1 ratio matched for gender, site

and closest in birth date to infected child) originally followed in

PACTS, and a newly HIV-infected comparison group of children and

adolescents, to compare psycho social development of perinatally

infected children to these other groups. Follow-up should be done at

least every 6 months, and include at a minimum: (1) Information on HIV-

related clinical conditions, HIV-related medication use/adherence,

hospitalizations, and survival; (2) all data points available from

charts on viral load testing and lymphocyte immuno phenotyping as part

of treatment protocols or clinical care; (3) storage of blood specimens

for other HIV-related testing; (4) data on growth, pubertal

development, neurocognitive functioning, and quality of life; and (5)

data on school related outcomes such as grade failure, receipt of

specific special services, and any available results of school

achievement or developmental testing.

III. Parent Communication Training Interventions With Longitudinal

Follow-up Among Populations of Color at High Risk for Infection for

STD's Including HIV

HIV Prevention messages must reach individuals early in life when

healthy attitudes are still developing which most likely will lead to

lifelong behavioral practices. Parents are in a unique and powerful

position to shape young people's attitudes, values, and behaviors, and

to socialize them to become healthy adults. Recent research suggests

that giving parents information and communication skills about

sexuality and HIV risk can be an effective HIV/AIDS prevention

strategy. Applications are invited to conduct randomized intervention

trials of parent communication training interventions with longitudinal

follow-up among populations of color at high risk for infection for

STD's including HIV. The intent is to examine the impact of a parental

communication training program (i.e., minimal, basic, enhanced skills

training) on parents' communication with their children and

[[Page 27996]]

the subsequent attitudes, beliefs and behaviors about sex and drug use

of their children over time.

B. Eligible Applicants

Applications may be submitted by public and private nonprofit

organizations and by governments and their agencies; that is,

universities, colleges, research institutions, hospitals, other public

and private nonprofit organizations, State and local governments or

their bona fide agents, and federally recognized Indian tribal

governments, Indian tribes, or Indian tribal organizations.

For the MIRIAD study, only institutions serving disadvantaged

communities with high HIV seroprevalence among women of childbearing

age (i.e., approximately 1 percent prevalence or higher) and the

ability to recruit and retain a minimum of 20 HIV-infected pregnant

women per year not receiving prenatal care or with unknown HIV

serostatus before 36 weeks are invited to participate in this study.

Note: Public Law 104-65 states that an organization described in

section 501(c)(4) of the Internal Revenue Code of 1986 that engages

in lobbying activities is not eligible to receive Federal funds

constituting an award, grant, cooperative agreement, contract, loan,

or any other form.

C. Availability of Funds

I. Approximately $2.7 million is available in FY 1999 to fund

approximately 5 to 6 awards for mother infant rapid intervention at

delivery (MIRIAD). It is expected that the average award will be

$500,000, ranging from $300,000 to $700,000.

II. Approximately $800,000 is available in FY 1999 to fund

approximately 4 competitive continuation projects for follow-up of

Perinatally HIV-infected children and a comparison group. It is

expected that the average award will be $200,000, ranging from $150,000

to $250,000.

III. Approximately $900,000 is available in FY 1999 to fund

approximately 3 awards for intervention trials of parent communication

training. It is expected that the average award will be $300,000,

ranging from $200,000 to $400,000.

It is expected that all awards will begin on or about September 1,

1999, and will be made for a 12-month budget period within a project

period of up to 5 years. Funding estimates may change.

Continuation awards within an approved project period will be made

on the basis of satisfactory progress as evidenced by required reports

and the availability of funds.

Funding Preference

Preference will be given to achieve geographical diversity (e.g.,

Northeast, South, Central, and West).

For the Perinatally-HIV Infected Children Study, preference will be

given to competing continuation applications from satisfactorily

performing projects over applications for projects not already

receiving support for follow-up of perinatally-HIV infected children.

D. Program Requirements

In conducting activities to achieve the purpose of these programs,

the recipient will be responsible for the activities listed under

Recipient Activities and CDC will be responsible for conducting

activities listed under CDC Activities:

1. Recipient Activities

Recipients addressing the same research issue should be willing to

participate in collaborative studies with other CDC-sponsored

researchers, including using common data collection instruments,

specimen collection protocols, and data management procedures, as

determined in post-award grantee planning conferences. Recipients will

be required to pool data for analysis and publication. Recipients are

also required to work collaboratively as a study wide group to:

a. Develop the research study protocols and standardized data

collection forms across sites.

b. Identify, recruit, obtain informed consent from, and enroll an

adequate number of study participants as determined by the study

protocol and the program requirements.

c. Continue to follow study participants as determined by the study

protocol.

d. Establish procedures to maintain the rights and confidentiality

of all study participants.

e. Perform laboratory tests (when appropriate) and data analysis as

determined in the study protocol.

f. Collaborate and share data and specimens (when appropriate) with

other collaborators to answer specific research questions.

g. Contribute blood specimens (at least every 6-12 months depending

on the protocol requirements) for shipment and storage at a centralized

repository system at CDC.

h. Conduct data analysis with all collaborators as well as present

and publish research findings.

2. CDC Activities

a. Provide technical assistance in the design and facilitate in the

overall research project.

b. Facilitate and assist in the development of a research protocol

for IRB (institutional review board) review by all cooperating

institutions participating in the research project. The CDC IRB will

review and approve the protocol initially and on at least an annual

basis until the research project is completed.

c. Assist in designing a data management system.

d. Assist in performance of selected laboratory tests.

e. Work collaboratively with investigators to help coordinate

research activities across sites involved in the same research project.

f. Assist in the analysis of research information and the

presentation and publication of research findings.

E. Application Content

Use the information in the Program Requirements, Other

Requirements, and Evaluation Criteria sections to develop the

application content. Your application will be evaluated on the criteria

listed, so it is important to follow them in laying out your program

plan. Follow the directions for completing the application that are

found in the Public Health Service (PHS) 398 kit.

F. Submission and Deadline

Submit the original and five copies of PHS-398 (OMB Number 0925-

0001) (adhere to the instructions on the Errata Instruction Sheet for

PHS 398). Forms are in the application kit. On or before July 19, 1999,

submit the application to the Grants Management Specialist identified

in the ``Where to Obtain Additional Information'' section of this

announcement.

Deadline: Applications shall be considered as meeting the deadline

if they are either:

(a) Received on or before the deadline date; or

(b) Sent on or before the deadline date and received in time for

submission to the independent review group. (Applicants must request a

legibly dated U.S. Postal Service postmark or obtain a legibly dated

receipt from a commercial carrier or U.S. Postal Service. Private

metered postmarks shall not be acceptable as proof of timely mailing.)

Applications which do not meet the criteria in (a) and (b) above will

not be considered, and will be returned to the applicant.

G. Evaluation Criteria

Each application will be evaluated individually against the

following criteria by an independent review group appointed by CDC.

Applicants will be

[[Page 27997]]

ranked on a scale of 100 maximum points according to the research area

identified. All applicants must state which research category they are

addressing.

I. Mother Infant Rapid Intervention At Delivery (MIRIAD)

1. Recruitment, Retention and Adherence to Study Protocol (30

points).

a. Extent of applicant's experience in perinatal and pediatric HIV

infection epidemiologic research.

b. Evidence of ability to successfully recruit and follow HIV-

infected mothers and infants in longitudinal research studies.

c. Evidence of approximately 1% or greater HIV sero prevalence

among pregnant women in the catchment area described in the

application.

d. Ability to recruit and retain at least 20 and ideally over 30

HIV-infected pregnant women annually fulfilling the objectives of the

MIRIAD study. Linkages with other area hospitals and a Community

Advisory Board are strongly encouraged.

e. Ability to organize and provide a round-the-clock counseling and

voluntary rapid HIV testing program among women in labor presenting

with unknown HIV status; or immediately postpartum in first two days

following delivery.

f. Evidence of ability to collect complete data including

interviews of mothers in the immediate postpartum period and to obtain

a sufficiently large blood sample from HIV-infected mothers enrolled in

MIRIAD around the time of delivery.

g. Evidence of ability to collect complete data and to obtain

regular blood samples from HIV-exposed infants, with at least one blood

sample during the first 48 hours after birth.

h. Ability to oversee specimen collection for the timely

processing, storage, and retrieval of laboratory specimens as needed

for MIRIAD studies. This includes transfer of certain specimens to a

central repository at CDC and transfer of other specimens to designated

laboratories for specific laboratory studies.

i. Evidence of capability to address informed consent issues,

enhance social support and foster adherence to the antiretroviral

prophylaxis regimen, with special attention directed at adherence to

the neonatal component of the regimen.

2. Description and Justification of Research Plans (30 points).

a. Extent of familiarity and quality of experience pertinent to

proposed research activities.

b. Understanding of the research objectives as evidenced by the

high quality and scientific rigor of the proposed plan for research and

a study design that is appropriate to answer research questions.

c. The inclusion of innovative approaches to investigate the

feasibility of obtaining informed consent during labor for voluntary

rapid HIV testing, rapid implementation of antiretroviral therapy given

at labor and delivery or to the neonate, and adherence to neonatal

antiretroviral therapy.

d. Extent to which the applicant demonstrates willingness to work

with all successful applicants on development of a common core research

protocol across funded sites.

e. Feasibility of plans to follow study participants. This includes

demonstration of the experience of the investigator in following HIV-

infected mothers and infants, and the comprehensiveness of the plan to

protect the rights and confidentiality of all participants.

f. Thoroughness of plans for data management, data analysis, and

laboratory analysis; reasonableness of data collected; and statistical

rigor.

g. Extent to which proposal demonstrates feasible plans for

coordinating research activities of multiple local clinical sites,

where appropriate, and with CDC. Letters of support from cooperating

organizations that demonstrate the nature and extent of such

cooperation should be included.

h. The degree to which the applicant has met the CDC Policy

requirements regarding the inclusion of women, ethnic and racial groups

in the proposed research. This includes:

(i) The proposed plan for the inclusion of racial and ethnic

minority populations for appropriate representation;

(ii) The proposed justification when representation is limited or

absent;

(iii) A statement as to whether the design of the study is adequate

to measure differences when warranted;

(iv) A statement as to whether the plans for recruitment and

outreach for study participants include the process of establishing

partnerships with communities and recognition of mutual benefits.

3. Research and Intervention Capability (20 points).

a. Applicant's ability to carry out the proposed research as

demonstrated by the training and experience of the proposed research

team and organizational setting, including demonstration of ability to

collect, manage, and analyze accurate data in a timely manner.

b. Demonstration of working relationships with proposed

investigators and extent to which services to be provided by external

experts or consultants are documented by memoranda of agreement.

c. Demonstration of epidemiologic, behavioral, clinical,

administrative, laboratory, data management and statistical analysis

expertise needed to conduct proposed research.

4. Staffing, Facilities and Time line (20 points).

a. Availability of qualified and experienced personnel with

sufficient time dedicated to the proposed project.

b. Clarity of the described duties and responsibilities of project

personnel.

c. Adequacy of plans for project oversight to assure quality of

data.

d. Adequacy of facilities, equipment, data management resources,

and systems for ensuring data security and patient confidentiality.

e. Adequacy of time line for completion of project activities.

5. Other (not scored)

a. Budget: The extent to which it is reasonable, clearly justified,

consistent with the intended use of funds, and allowable. All budget

categories should be itemized.

b. Human Subjects: Does the application adequately address the

requirements of Title 45 CFR Part 46 for the protection of human

subjects? ____Yes ____No Comments:

II. Follow-up of Perinatally HIV-Infected Children

1. Retention and Adherence to Study Protocol (20 points).

a. Extent of applicant's experience in perinatal and pediatric HIV

infection epidemiologic research.

b. Evidence of ability to successfully follow HIV-infected children

in longitudinal research studies.

c. Evidence of ability to collect complete clinical, laboratory and

behavioral data and to obtain regular blood samples from HIV-infected

children; and demonstration of capability to re-enroll and follow a 1:1

ratio of HIV exposed but uninfected children from the PACTS cohort

originally followed at the site and/or a comparison group of newly HIV-

infected children and adolescents.

2. Description and Justification of Research Plans (30 points).

a. Extent of familiarity and quality of experience pertinent to

proposed research activities.

b. Understanding of the research objectives as evidenced by the

high quality of the proposed plan for research.

c. Originality of research, extent to which it does not replicate

past or

[[Page 27998]]

present research efforts, and direct relevance of research to guiding

current efforts to prevent HIV disease progression in children.

d. Feasibility of plans to follow study participants, and adequacy

of sample size to address research questions. This includes

demonstration of the experience of the investigator in following such

persons, and the comprehensiveness of the plan to protect the rights

and confidentiality of all participants.

e. Thoroughness of plans for data management, data analysis, and

laboratory analysis; reasonableness of data collected; and statistical

rigor.

f. Extent to which proposal demonstrates feasible plans for

coordinating research activities across multiple clinical sites, where

appropriate, and with CDC. Letters of support from cooperating

organizations that demonstrate the nature and extent of such

cooperation should be included.

g. The degree to which the applicant has met the CDC Policy

requirements regarding the inclusion of women, ethnic and racial groups

in the proposed research. This includes:

(i) The proposed plan for the inclusion of racial and ethnic

minority populations for appropriate representation;

(ii) The proposed justification when representation is limited or

absent;

(iii) A statement as to whether the design of the study is adequate

to measure differences when warranted;

(iv) A statement as to whether the plans for recruitment and

outreach for study participants include the process of establishing

partnerships with communities and recognition of mutual benefits.

3. Research Capability (30 points).

a. Applicant's ability to carry out the proposed research as

demonstrated by the training and experience of the proposed research

team, including demonstration of ability to collect, manage, and

analyze accurate data in a timely manner.

b. Demonstration of working relationships with proposed

investigators.

c. Demonstration of epidemiologic, behavioral, clinical,

administrative, laboratory, data management and statistical analysis

expertise needed to conduct proposed research.

4. Staffing, Facilities and Time Line (20 points).

a. Availability of qualified and experienced personnel, including

individuals with biomedical, behavioral, and epidemiological expertise.

b. Clarity of the described duties and responsibilities of project

personnel.

c. Adequacy of plans for project oversight to assure quality of

data.

d. Adequacy of facilities, equipment, data management resources,

and systems for ensuring data security and patient confidentiality.

e. Adequacy of time line for completion of project activities.

5. Other (not scored).

a. Budget: The extent to which it is reasonable, clearly justified,

consistent with the intended use of funds, and allowable. All budget

categories should be itemized.

b. Human Subjects: Does the application adequately address the

requirements of Title 45 CFR Part 46 for the protection of human

subjects? ____Yes ____No Comments:

III. Parent Communication Training Interventions With Longitudinal

Follow-up Among Populations of Color at High Risk for Infection for

STD's Including HIV

1. Description, Justification and Originality of Research Plans (25

points).

a. The inclusion of a detailed review of the scientific literature

and theoretical underpinnings on which the proposed research plan and

intervention are based. Application of science and theory to guide/

justify the generation and articulation of specific research questions

and hypotheses.

b. The originality of the proposed research and the extent to which

it builds on old science, extends or creates new science and does not

replicate past or present research efforts.

2. Familiarity with developmental and behavioral issues of children

and families. Access and ability to recruit, retain, and conduct

research with cohorts of 8 and 11 year old children and their families

(25 points).

a. The inclusion of abstracts, presentations, and manuscripts that

demonstrate the applicant's prior research expertise with children and

families, with particular regard to family communication, family based

interventions, and familial factors influencing risk taking behaviors.

b. Quality and description of methods used to identify, recruit ,

retain, and longitudinally follow cohorts of 8 and 11 year old children

and their families for 5 years, including the documented ability to

recruit and retain adequate numbers of study participants.

c. Quality, diversity, and description of methods used to collect

quantitative data during research, intervention, longitudinal tracking,

and evaluation phases of the research study with cohorts of 8 and 11

year old children and their families for 5 years.

d. The inclusion of abstracts, presentations, and manuscripts that

demonstrate the applicants ability to conduct longitudinal research

with children and families.

3. Intervention research plan (25 points).

a. Extent to which the proposed research design and methods are

appropriate for an intervention trial responsive to this request,

including randomization procedures, statistical power to detect

hypothesized differences, primary (attitudinal, cognitive, behavioral

and biological) and secondary (relevant mediating variables) outcome

measures, the reliability and validity of measures that will be used,

and procedures for maximizing external and internal validity (e.g.,

sampling strategies and retention procedures, respectively).

b. Appropriateness of description and justification of the proposed

research hypotheses, intervention plan, and intervention outcome

measures that will be addressed as part of the intervention trial.

c. Quality and scientific rigor of the research design, methods,

hypotheses, plan, and outcome measures that will be employed in the

intervention trial.

d. Extent to which the applicant demonstrates willingness to work

with CDC staff and consultants on development of a common research and

intervention protocol across sites.

e. Adequacy of procedures for obtaining informed consent and

maintaining participant confidentiality.

f. The degree to which the applicant has met the CDC Policy

requirements regarding the inclusion of women, ethnic and racial groups

in the proposed research. This includes:

(i) The proposed plan for the inclusion of racial and ethnic

minority populations for appropriate representation;

(ii) The proposed justification when representation is limited or

absent;

(iii) A statement as to whether the design of the study is adequate

to measure differences when warranted;

(iv) A statement as to whether the plans for recruitment and

outreach for study participants include the process of establishing

partnerships with communities and recognition of mutual benefits.

4. Research and intervention capability (15 points).

a. Applicant's ability to carry out the proposed research as

demonstrated by the training and experience of the proposed research

team and organizational setting, including

[[Page 27999]]

demonstration of previous behavioral/clinical interventions carried

out.

b. Ability of the applicant to conduct the proposed research as

reflected in the training, research, and behavioral intervention

experience of staff members.

c. Extent to which services to be provided by external experts,

consultants, or collaborating agencies are documented by memoranda of

agreement in the appendix.

5. Staffing, facilities, and time line (10 points).

a. Availability of qualified and experienced personnel with

sufficient time dedicated to the proposed project. Presence of

behavioral scientists in key leadership positions on the project.

b. Clarity of the described duties and responsibilities of project

personnel.

c. Adequacy of the facilities, equipment, data management

resources, and systems for ensuring data security.

d. Specificity and reasonableness of time line.

6. Other (not scored).

a. Budget: The extent to which it is reasonable, clearly justified,

consistent with the intended use of funds, and allowable. All budget

categories should be itemized.

b. Human Subjects: Does the application adequately address the

requirements of Title 45 CFR part 46 for the protection of human

subjects? ____Yes ____No Comments:

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two copies of

1. Annual progress report;

2. Financial status report, no more than 90 days after the end of

the budget period; and

3. Final financial status and performance reports, no more than 90

days after the end of the project period.

Send all reports to the Grants Management Specialist identified in

the ``Where to Obtain Additional Information'' section of this

announcement.

The following additional requirements are applicable to this

program. For a complete description of each, see the document entitled

``Descriptions of Other Requirements'' in the GMB homepage under

Program Announcements.

AR-1 Human Subjects Requirements.

AR-2 Requirements for Inclusion of Women and Racial and Ethnic

Minorities in Research.

AR-4 HIV/AIDS Confidentiality Provisions.

AR-5 HIV Program Review Panel Requirements.

AR-6 Patient Care

AR-7 Executive Order 12372 Review

AR-8 Public Health System Reporting Requirements

AR-9 Paperwork Reduction Act Requirements

R-10 Smoke-Free Workplace Requirements

AR-11 Healthy People 2000

AR-12 Lobbying Restrictions

I. Authority and Catalog of Federal Domestic Assistance Number

This program is authorized under sections 301(a) and 317 (k)(2)of

the Public Health Service Act, (42 U.S.C. 241(a) and 247(k) (2)), as

amended. The Catalog of Federal Domestic Assistance number is 93.943.

J. Where To Obtain Additional Information

To receive additional written information and to request an

application kit, call 1-888-GRANTS4 (1-888 472-6874). You will be asked

to leave your name and address and will be instructed to identify the

Announcement number of interest.

If you have questions after reviewing the contents of all the

documents, business management technical assistance may be obtained

from: Curtis Meusel, Grants Management Specialist, Grants Management

Branch, Procurement and Grants Office, Announcement 99102, Centers for

Disease Control and Prevention (CDC), Colgate Building Room 3000, 2920

Brandywine Road, M/S E-15, Atlanta, GA 30341, Telephone (770) 488-2738,

Email address [email protected].

For program technical assistance, contact: Jeff Efird, MPA, Deputy

Chief, Epidemiology Branch, Division of HIV/AIDS Prevention

Surveillance & Epidemiology, National Center for HIV, STD, TB

Prevention, Centers for Disease Control and Prevention (CDC), 1600

Clifton Road, NE., Mailstop E-45 Atlanta, Georgia 30333, Telephone

(404) 639-6130, E-mail [email protected].

See also the CDC home page on the Internet to view and download all

CDC funding opportunities (i.e., program announcements) and applicable

application forms: HTTP://WWW.CDC.GOV.

Eligible applicants are encouraged to call before developing and

submitting their applications.

Dated: May 18, 1999.

John L. Williams,

Director, Procurement and Grants Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 99-12996 Filed 5-21-99; 8:45 am]

BILLING CODE 4163-18-P